Woodline Partners LP Viridian Therapeutics, Inc.\De Transaction History
Woodline Partners LP
- $11 Billion
- Q3 2024
A detailed history of Woodline Partners LP transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Woodline Partners LP holds 818,995 shares of VRDN stock, worth $15.8 Million. This represents 0.17% of its overall portfolio holdings.
Number of Shares
818,995
Previous 400,915
104.28%
Holding current value
$15.8 Million
Previous $5.22 Million
257.28%
% of portfolio
0.17%
Previous 0.05%
Shares
10 transactions
Others Institutions Holding VRDN
# of Institutions
178Shares Held
76.6MCall Options Held
581KPut Options Held
439K-
Black Rock Inc. New York, NY4.77MShares$92.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.42MShares$85.4 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$75 Million9.15% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.75MShares$72.4 Million3.15% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.45MShares$66.5 Million12.74% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $770M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...